PDGFRB and chondrosarcoma: For instance, in a case of metastatic chondrosarcoma refractory to front-line chemotherapy, second-line treatment with the PDGFR inhibitor pazopanib resulted in an objective effect lasting for more than 6 months with marked improvements in the patient’s symptomatology and common condition [58].